Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2020 13:27 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market

NEWTOWN, Pa., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
December 31, 2019 11:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market

NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
December 19, 2019 13:44 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market

NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
December 18, 2019 09:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market

Proceeds provide sufficient funds to extend operations and ongoing trials late into the fourth quarter of 2020Company does not intend to raise additional capital for ninety days following the closing...
December 18, 2019 09:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand

Specialised Therapeutics receives exclusive license to commercialize rigosertib in Australia and New ZealandOnconova to be eligible to receive up to US $30.4 million in clinical, regulatory, and...
December 17, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.; Pint Pharma

Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil

The INSPIRE Trial enters the final stage of enrollment after surpassing 90% of the required number of randomized patients in November 2019 Pint Pharma Facilitates Opening of Phase 3 INSPIRE Trial in...
December 10, 2019 15:07 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market

NEWTOWN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
December 09, 2019 09:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting

Genomic Profiling at Study Entry in Patients with Higher Risk Myelodysplastic Syndrome (HR-MDS) Following Hypomethylating (HMA) Failure: Results From the INSPIRE Trial, including RAS and other...
December 09, 2019 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market

NEWTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
December 06, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel...